Recent clinical trials based on human pluripotent stem cell-derived retinal pigment epithelium cells (hPSC-RPE cells) were clearly a success regarding safety outcomes. However the delivery strategy of a cell suspension, while being a smart implementation of a cell therapy, might not be sufficient to achieve the best results. More complex reconstructed tissue formulations are required, both to improve functionality and to target pathological conditions with altered Bruch’s membrane like age-related macular degeneration (AMD). Herein, we describe the various options regarding the stem cell source choices and the different strategies elaborated in the recent years to develop engineered RPE sheets amenable for regenerative therapies.
CITATION STYLE
Ben M’Barek, K., Habeler, W., & Monville, C. (2018). Stem cell-based RPE therapy for retinal diseases: Engineering 3D tissues amenable for regenerative medicine. In Advances in Experimental Medicine and Biology (Vol. 1074, pp. 625–632). Springer New York LLC. https://doi.org/10.1007/978-3-319-75402-4_76
Mendeley helps you to discover research relevant for your work.